Literature DB >> 6661842

Thromboembolic complications of pregnancy.

J C Bolan.   

Abstract

Physiologic changes in clotting parameters and venous flow during pregnancy increase the likelihood of deep venous thrombosis. Conditions that place the pregnant patient at a higher risk include a previous history of thromboembolic disease and surgery or bedrest for any reason during the pregnancy. In the high-risk patient, prophylactic therapy with low-dose heparin is advised beginning around the 34th week of pregnancy and continuing until 4-6 weeks after delivery. The clinical diagnosis of thrombophlebitis or pulmonary embolus is unreliable and should be confirmed objectively before therapy is started. During pregnancy, doppler ultrasound and impedance plethysmography should be the first-line diagnostic tests, but one should seek confirmation with venography if in doubt. The preferred method of therapy for the acute thrombolic event is full anticoagulation with continuous intravenous heparin from 7-10 days, followed by therapy with subcutaneous heparin for the remainder of the pregnancy and the puerperium, although there is considerable controversy regarding long-term therapy. Fibrinolytic agents have little place in pregnancy, and surgical therapy should be reserved for the critically ill patient only.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661842     DOI: 10.1097/00003081-198312000-00014

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  3 in total

Review 1.  Anticoagulants in pregnancy.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1995-08

2.  Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour.

Authors:  T Flossdorf; M Breulmann; H B Hopf
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Ten year mortality and causes of death in patients with rheumatoid arthritis.

Authors:  O Mutru; M Laakso; H Isomäki; K Koota
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.